Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2015 3
2016 3
2017 3
2018 1
2019 1
2020 1
2021 4
2022 6
2023 5
2024 9
2025 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

39 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial.
Becker JC, Ugurel S, Leiter U, Meier F, Gutzmer R, Haferkamp S, Zimmer L, Livingstone E, Eigentler TK, Hauschild A, Kiecker F, Hassel JC, Mohr P, Fluck M, Thomas I, Garzarolli M, Grimmelmann I, Drexler K, Spillner AN, Eckhardt S, Schadendorf D; DeCOG. Becker JC, et al. Lancet. 2023 Sep 2;402(10404):798-808. doi: 10.1016/S0140-6736(23)00769-9. Epub 2023 Jul 11. Lancet. 2023. PMID: 37451295 Clinical Trial.
Stringent monitoring can decrease mortality of immune checkpoint inhibitor induced cardiotoxicity.
Wang Y, Ertl C, Schmitt C, Hammann L, Kramer R, Grabmaier U, Schöberl F, Anz D, Piseddu I, Pesch G, Vera J, Froehlich W, Weckbach L, Tomsitz D, Loquai C, Zimmer L, Mangana J, Dummer R, Gutzmer R, Klespe KC, Stege H, Meiss F, Thoms KM, Terheyden P, Bröckelmann PJ, Johnson DB, French LE, Heinzerling L. Wang Y, et al. Among authors: tomsitz d. Front Cardiovasc Med. 2024 Jun 10;11:1408586. doi: 10.3389/fcvm.2024.1408586. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 38915743 Free PMC article.
Checkpoint-inhibitor induced Polyserositis with Edema.
Zierold S, Akcetin LS, Gresser E, Maier AM, König A, Kramer R, Theurich S, Tomsitz D, Erdmann M, French LE, Rudelius M, Heinzerling L. Zierold S, et al. Among authors: tomsitz d. Cancer Immunol Immunother. 2022 Dec;71(12):3087-3092. doi: 10.1007/s00262-022-03211-7. Epub 2022 May 16. Cancer Immunol Immunother. 2022. PMID: 35576074 Free PMC article.
Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors.
Ruf T, Kramer R, Forschner A, Leiter U, Meier F, Reinhardt L, Dücker P, Ertl C, Tomsitz D, Tietze JK, Gutzmer R, Dabrowski E, Zimmer L, Gesierich A, Zierold S, French LE, Eigentler T, Amaral T, Heinzerling L. Ruf T, et al. Among authors: tomsitz d. Eur J Cancer. 2024 May;203:114028. doi: 10.1016/j.ejca.2024.114028. Epub 2024 Mar 27. Eur J Cancer. 2024. PMID: 38652976 Free article.
Tumor lysis syndrome induced by tebentafusp.
Ruf T, Leonhardt A, Anz D, Kunz WG, Röhrle N, Foerster P, Tomsitz D, French LE, Seegräber M, Heinzerling L. Ruf T, et al. Among authors: tomsitz d. Immunotherapy. 2023 Nov;15(16):1363-1368. doi: 10.2217/imt-2023-0093. Epub 2023 Sep 4. Immunotherapy. 2023. PMID: 37661909
39 results